Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00789672 · ClinicalTrials.gov registry record · Phase 2

Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia

A Phase 2 study, sponsored by Jaeb Center for Health Research.

Completed
Registry status
Phase 2
Development phase
33
Enrollment target

NCT00789672 is a Phase 2 study that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 33 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00789672, a Phase 2 study, has completed, sponsored by Jaeb Center for Health Research.

COMPLETED
Registry status
Phase 2
Development phase
33 participants
Enrollment target

Study Summary

This pilot study is being conducted as a prelude to a randomized trial to compare levodopa/carbidopa plus patching versus patching alone. The purpose of the pilot study is to demonstrate recruitment potential, to provide prospective data on the tolerability of levodopa as a treatment for amblyopia, to provide limited data on its safety, to provide limited data on it's efficiency, and to provide data to assist in selecting a dose to use in a subsequent phase 3 randomized trial. In addition, this study will provide the opportunity for investigators to gain experience in using levodopa prior to a randomized trial.

Interventions

  • DRUG levodopa/carbidopa
  • DEVICE patching

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2009-01
Est. Completion 2009-12
Phase Phase 2

Sponsor

Jaeb Center for Health Research

119 total trials

What the Registry Record Tells You About NCT00789672

The ClinicalTrials.gov registry entry for NCT00789672 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which levodopa/carbidopa is the first listed.

NCT00789672 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00789672 about?

NCT00789672 is a clinical study titled "Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia". This pilot study is being conducted as a prelude to a randomized trial to compare levodopa/carbidopa plus patching versus patching alone. The purpose of the pilot study is to demonstrate recruitment potential, to provide prospective data on the tolerability of levodopa as a treatment for amblyopia, ...

What is the current status of trial NCT00789672?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2009-01. Estimated completion is 2009-12.

What interventions are being tested in trial NCT00789672?

The interventions under investigation include: levodopa/carbidopa (DRUG), patching (DEVICE).

Who is sponsoring clinical trial NCT00789672?

This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.